Use of H3K9me3 modulation for enhancing cognitive function
US-10272093-B2 · Apr 30, 2019 · US
Use of H3K9me3 modulation for enhancing cognitive function
US10849910B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10849910-B2 |
| Application number | US-201916354996-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2019 |
| Priority date | Jun 8, 2015 |
| Publication date | Dec 1, 2020 |
| Grant date | Dec 1, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition for reversing cognition loss in an animal subject in need thereof, the composition comprising: a therapeutically effective amount of a SUV39H1 inhibitor compound ETP69, and a pharmaceutical cognitive enhancer. 2. The composition of claim 1 , wherein the cognitive enhancer is a cholinesterase inhibitor selected from a group comprising tacrine, donepezil, rivastigmine, and galantamine. 3. The composition of claim 1 , wherein the cognitive enhancer is an NMDA antagonist or an NMDA agonist. 4. The composition of claim 1 , wherein the cognitive enhancer is an ampakine. 5. The composition of claim 1 , wherein the cognitive enhancer is a BZD/GABA receptor complex modulator. 6. The composition of claim 1 , wherein the cognitive enhancer is a serotonin antagonist. 7. The composition of claim 1 , wherein the cognitive enhancer is a nicotinic class compound. 8. The composition of claim 1 , wherein the cognitive enhancer is a muscarinic class compound. 9. The composition of claim 1 , wherein the cognitive enhancer is a PDE inhibitor. 10. The composition of claim 1 , wherein the cognitive enhancer is a G protein class compound. 11. The composition of claim 1 , wherein the cognitive enhancer is a channel modulator. 12. The composition of claim 1 , wherein the cognitive enhancer is an immunotherapeutic class compound. 13. The composition of claim 1 , wherein the cognitive enhancer is an anti-amyloid or amyloid lowering agent. 14. The composition of claim 1 , wherein the cognitive enhancer is a statin or a PPARS modulator. 15. A composition for reversing cognition loss in an animal subject in need thereof, the composition comprising: a therapeutically effective amount of an analog of ETP69 compound, and a pharmaceutical cognitive enhancer.
Assignees
Inventors
Classifications
- C07D513/18Primary
Bridged systems · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anxiolytics · CPC title
Drugs for disorders of the nervous system · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10849910B2 cover?
- Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification C07D513/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).